CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

Colin W. Steele(Cancer Research UK), Saadia A. Karim(Cancer Research UK), Joshua D.G. Leach(Cancer Research UK), Peter J. Bailey(University of Glasgow), Rosanna Upstill‐Goddard(University of Glasgow), Loveena Rishi(University of Glasgow), Mona Foth(Cancer Research UK), Sheila Bryson(Cancer Research UK), Karen McDaid(AstraZeneca (United Kingdom)), Zena Wilson(AstraZeneca (United Kingdom)), Catherine A. Eberlein(AstraZeneca (United Kingdom)), Juliana Candido, Mairi Clarke(University of Glasgow), Colin Nixon(Cancer Research UK), John Connelly(Cancer Research UK), Nigel B. Jamieson(Glasgow Royal Infirmary), C. Ross Carter(Glasgow Royal Infirmary), Frances R. Balkwill, David K. Chang(University of Glasgow), T.R. Jeffry Evans(Cancer Research UK), Douglas Strathdee(Cancer Research UK), Andrew V. Biankin(University of Glasgow), Robert J. B. Nibbs(University of Glasgow), Simon T. Barry(AstraZeneca (United Kingdom)), Owen J. Sansom(Cancer Research UK), Jennifer P. Morton(Cancer Research UK)
Cancer Cell
June 1, 2016
10.1016/j.ccell.2016.04.014
Cited by 835Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis